Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21171907 | 0.83 | S1PR3 (0.46) | CYP1A2SLC1A3SLC1A2SLC1A1CETP | |
| SCHEMBL21172154 | 0.83 | CETP (0.47) | CETPS1PR3 | |
| SCHEMBL21171795 | 0.83 | FNTA (0.43) | CYP1A2SLC1A3SLC1A2SLC1A1TACR1 | |
| SCHEMBL21171902 | 0.83 | MC4R (0.42) | CYP1A2CETPMMEALOX5HDAC1 | |
| SCHEMBL21171739 | 0.83 | KDR (0.40) | RAB9ANPC1MAPTHDAC1HDAC8 | |
| SCHEMBL21533733 | 0.80 | TGM2 (0.49) | MAPTTGM2HDAC1HDAC8 | |
| SCHEMBL24486727 | 0.79 | CETP (0.49) | CETPS1PR3 | |
| SCHEMBL6519797 | 0.78 | SLC1A3 (0.48) | CYP1A2SLC1A3SLC1A2SLC1A1TACR1 | |
| SCHEMBL21171901 | 0.77 | SCN1A (0.46) | CYP1A2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL21171732 | 0.76 | SLC1A3 (0.42) | CYP1A2SLC1A3SLC1A2SLC1A1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11353461-B2 | Methods of enhancing MS detection of tagged glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | WATERS TECHNOLOGIES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | WATERS TECHNOLOGIES CORPORATION (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190219587-A1 | METHODS OF ENHANCING MS DETECTION OF TAGGED GLYCANS | WATERS TECHNOLOGIES CORPORATION | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190331669-A1 | FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES THROUGH REDUCTIVE AMINATION FOR ENHANCED MS SIGNALS | FUT5, FUT6, OGT | CYP1A2 2545/4885SLC1A3 2679/4885SLC1A2 2869/4885 |
| US-11061023-B2 | Fluorescence tagging of glycans and other biomolecules through reductive amination for enhanced MS signals | FUT5, FUT6, OGT | CYP1A2 2545/4885SLC1A3 2679/4885SLC1A2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.